1/9/2025

Bumetanide Injection

Products Affected - Description

- Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
- Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10

Reason for the Shortage

- Fresenius Kabi has bumetanide injection available.
- Glenmark has bumetanide injection available.
- Hikma did not provide a reason for the shortage.
- Novadoz has bumetanide injection available.
- Pfizer discontinued bumetanide injection in August 2022.
- Sagent has bumetanide injection available.

Available Products

- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 10 mL vial, 10 count, NDC 65219-0570-10
- Bumetanide injection, Fresenius Kabi, 0.25 mg/mL, 4 mL vial, 10 count, NDC 65219-0570-04
- Bumetanide injection, Glenmark, 0.25 mg/mL, 10 mL vial, 10 count, NDC 68462-0470-54
- Bumetanide injection, Glenmark, 0.25 mg/mL, 4 mL vial, 10 count, NDC 68462-0469-54
- Bumetanide injection, Novadoz, 0.25 mg/mL, 10 mL vial, 10 count, NDC 72205-0102-07
- Bumetanide injection, Novadoz, 0.25 mg/mL, 4 mL vial, 10 count, NDC 72205-0101-07
- Bumetanide injection, Sagent, 0.25 mg/mL, 10 mL vial, 10 count, NDC 25021-0321-10
- Bumetanide injection, Sagent, 0.25 mg/mL, 4 mL vial, 10 count, NDC 25021-0321-04

Estimated Resupply Dates

- Hikma has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of mid-January 2025.

Updated

Updated January 9, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.